The selectins interact in important normal and pathological situations with certain sialylated, fucosylated glycoconjugate ligands containing sialyl Lewis x (Neu5Acα2-3Galβ1-4(Fuc-α1-3)GlcNAc). Much effort has gone into the synthesis of sialylated and sulfated Lewis x analogs as competitive ligands for the selectins. Since the natural selectin ligands GlyCAM-1 and PSGL-1 carry sialyl Lewis x as part of a branched Core 2 O-linked structure, we recently synthesized Galβ1-4(Fuc-α1-3)GlcNAcβ1-6(SE-3Galβ1-3)GalNAc1αOMe and found it to be a moderately superior ligand for L and P-selectin (Koenig et al., Glycobiology 7, 79-93, 1997). Other studies have shown that sulfate esters can replace sialic acid in some selectin ligands (Yeun et al., Biochemistry, 31, 9126-9131, 1992; Imai et al., Nature, 361, 555, 1993). Based upon these observations, we hypothesized that Neu5Acα2-3Galβ1-3Gal-NAc might have the capability of interacting with L-and P-selectin. To examine this hypothesis, we synthesized Galβ1-4(Fucα1-3)GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)-GalNAcα1-OB, which was found to be 2-to 3-fold better than sialyl Le x for P and L selectin, respectively. We also report the synthesis of an unusual structure GalNAcβ1-4(Fucα1-3)GlcNAcβ1-OMe (GalNAc-Lewis x -O-methyl glycoside), which also proved to be a better inhibitor of L-and P-selectin than sialyl Lewis x -OMe. Combining this with our knowledge of Core 2 branched structures, we have synthesized a molecule that is 5-to 6-fold better at inhibiting L-and P-selectin than sialyl Lewis x -OMe, By contrast to unbranched structures, substitution of a sulfate ester group for a sialic acid residue in such a molecule resulted in a considerable loss of inhibition ability. Thus, the combination of a sialic acid residue on the primary (β1-3) arm, and a modified Le x unit on the branched (β1-6) arm on an O-linked Core 2 structure generated a monovalent synthetic oliogosaccharide inhibitor superior to SLe x for both L-and P-selectin.
Introduction
The selectins are mammalian lectins that mediate the early steps of recruitment of leukocytes from the bloodstream in a variety of normal and pathological situations (see Bevilacqua and Nelson, 1993; Rosen and Bertozzi, 1994; Varki 1994 Varki , 1997 Lasky, 1995; Lowe and Ward, 1997; McEver and Cummings, 1997 , for reviews). All three members of this family of adhesion molecules (L-, P-, and E selectin) have amino terminal C-type lectin domains that originally predicted their ability to bind carbohydrates. The role of sialic acids in ligand recognition by the selectins was also evident from early studies. A landmark event in this field occurred when several groups independently reported that the selectins recognize sialylated fucosylated ligands containing the sialyl Le x motif (SLe x ) Neu5Acα2-3Galβ1-4 (Fuc-α1-3)GlcNAcβ1-(structure 1) (Phillips et al., 1990; Walz, 1990; Brandley, 1990) . Later it was shown that sialyl Le a type structures can also bind with selectins (Berg et al., 1991) . Also, Grinell et al., (1994) demonstrated that an uncommon sequence GalNAc-β1-4(Fucα1-3)GlcNAc (GalNAc-Le x ) occurred as a terminal structure on certain recombinant glycoproteins, and that it was a better inhibitor than SLe x for E-selectin.
It has also been well documented that the sulfate group can replace sialic acid in some instances as ligands for selectins (Yuen et al., 1992; Imai et al., 1993) . One of us (K.M.) was the first to synthesize 3-O-sulfoLe x SE-3Galβ1-4(Fucα1-3)GlcNAc (Chandrasekaran et al., 1991 (Chandrasekaran et al., , 1992 . Synthetic sulfo Le x derivative SE-3Galβ1-4(Fucα1-3)GlcNAcβ1-OMe 2 is recognized by all three selectins (Koenig et al., 1997) . These findings stimulated interest in the chemical and enzymatic synthesis of SLe x 1 and its isomer SLe a , Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-OMe (structure 3), their sulfated analogs and other modified structures related to these motifs (for example, Nicolaou et al., 1991 Nicolaou et al., , 1993 Tyrrel et al., 1991; Maaheimo et al., 1995; Bamford et al., 1996; Dupre et al., 1996; Marron et al., 1996; Sanders et al., 1996; Sprengard et al., 1996; Tsuboi et al., 1996; Woltering et al., 1996) .
Most of the efforts towards the procurement of such small molecule inhibitory ligands for selectins have been centered on the synthesis of mimics of SLe x type structures. Of note, the affinity of selectins for all these synthetic analogs appear to be much poorer than those of the natural glycoconjugate ligands such as GlyCAM-1, CD34 (Baumheiter et al., 1993; Hemmerich 1994 Hemmerich , 1995 , P-selectin glycoprotein ligand-1 (PSGL-I) (Moore et al., 1994; Wilkins et al., 1996) , and mucosal cell adhesion molecule (MadCAM-I) (Berg et al., 1993) , all of which are mucin type glycoproteins carrying large numbers of O-linked chains which include sialylated fucosylated sequences (Krall, 1997) .
The complex chains of O-linked glycoproteins consist of three distinct regions: core, backbone, and nonreducing terminus. The core structures are unique to O-linked glycoproteins, while the backbone and nonreducing terminus can be found in glycopeptides and also as part of N-linked glycoproteins. Among the known core structures (Schachter, 1986; Varki and Marth, 1995) in which GalNAc is α-linked to Ser/Thr, Core 2, GlcNAc-β(1-6)[Galβ(1-3)]GalNAcα1-O Ser/Thr, appears to be the most prominent among these six structures, and our synthetic selectin inhibitor 27 contains this same Core 2 structure. A brief account of our rationale for the synthesis of this inhibitor and its analogs follows.
Structural studies on the carbohydrate moieties of these ligands are only available for PSGL-1 and GlyCAM-1. Surprisingly, PSGL-1 is not heavily fucosylated, and the majority of O-glycans are disialylated or neutral forms of core 2 structures (Wilkins et al., 1996) . The following Core 2 branched SLe x containing structure has been reported as a significant component of both PSGL-1 and GlyCAM-1 (Hemmerich et al., 1995) :
However, according to Hemmerich (1995) , sulfate was reported to be present at the C-6 position of galactose, or 6 position of GlcNAc of the SLe x moiety linked to the C-6 position of GalNAc (structures 5 and 6). We therefore recently synthesized Neu5Acα2-3(SE-6Galβ1-4(Fucα1-3)GlcNAcβ1-OMe (structure 7) . However, our data indicate that this is neither a superior nor a specific ligand for L-selectin (Koenig et al., 1997) . The only obvious difference was that recognition by E-selectin was lost upon sulfation. The isomeric compound Neu5Acα2-3Galβ1-4(Fucα1-3)SE-6GlcNAcβ1-3Gal was synthesized by Scudder et al. (1994) and found to be only moderately superior to SLe x as an inhibitor of L-selectin.
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One explanation of the lack of high affinity of 6 and 6′-sulfo Lewis x for L-selectin (compared to native ligand of GLYCAM-1) could be that the whole carbohydrate moiety represented in 5 and 6 is involved in interaction with L-selectin. In other words, the Neu5Acα2-3Galβ1-3GalNAc-moiety of the Core 2 mucin structure might exert an appreciable impact on binding of L-selectin along with sulfated sialyl Lewis x linked at C-6 position in structures 5 and 6. Based on these data, we decided to examine the role of the Neu5Acα2-3Galβ1-3GalNAc sequence by synthesizing Core 2 branched structures. For example, we synthesized structure 34:
which was better than Sle x .
We have now synthesized GalNAcLe x -β-OMe and studied its inhibitory properties towards all three selectins. We have combined this with our knowledge of the properties of the sialylated Core 2 structures to rationally design a better inhibitor 27 for L-and P-selectin. Compound R E-Selectin P-Selectin L-Selectin 1 Neu5Acα2-3Galβ 550 ± 40 500 ± 25 600 ± 30
18 GalNAcβ 500 ± 120 400 ± 100 300 ± 100
The compounds shown were tested in an ELISA competition assay against the binding of recombinant selectins as described (Materials and methods).
IC 50 values (µM) against immobilized SLe x are the mean values of three separate experiments, and were calculated as described under Materials and methods. 
Results and discussion
A series of branched structures have been examined for inhibition of these three selectins. Synthetic strategies for the synthesis of oligosaccharides represented by structures 32 and 33 (Table III) whereas synthesis of 34 will be published elsewhere. In the present studies, under Materials and methods we have described the synthesis of 18 (Table I) , 24, 27 and 31 (Table II) . Figure 1 represents the four key 1-thio glycosyl donors employed in our synthetic schemes 1-4 depending upon the target structures. For introduction of GalNAcβ-linkage, we have utilized a key glycosyl donor phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-α/β-D-galactopyranoside (11). Compound 11 was prepared by treatment of known 1,3,4,6-tetra-O-acetyl-2-deoxy-2-phthalimido-α/β-D-galactopyranose (10) (Ogawa, 1992) with thiophenol in dichloromethane and in the presence of borontrifluoride-ethearate. Compound (11) existed largely as the β-anomer (α/β ratio 1:4) as judged by its 1 H NMR spectrum. Scheme I represents the synthesis of 18 and key glycosyl donor 20 for the synthesis of GalNAc Le x linked compounds. Regioselective acylation of methyl 3-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 12 (Alais and David, 1990) with acetyl chloride in pyridine afforded the 6-O-acetyl derivative (13) in 79% yield. Glycosylation (catalyzed by N-iodosuccinimide-triflic acid (Veeneman et al., 1990) of 13 with donor 11 gave (14) in 52% yield. Hydrogenolytic cleavage of the benzyl group of 14 in glacial acetic acid and in the presence of 10% palladium-on-carbon furnished the partially protected disaccharide (15). α-L-Fucosylation of 15 with the tri-O-benzyl thiophenyl donor (16) in the presence of N-iodosuccinimide-triflic acid (Scheme I) afforded the fully protected trisaccharide derivative (17) in 68% yield. Compound 17 was converted, in 76% yield, into the diphthaloyl peracetate (19) by hydrogenolysis (glacial acetic acid-10% Pd-C), followed by acetolysis (acetic anhydrideacetic-acid-sulfuric acid). Compound 19 was, in turn, converted (49% yield) into the key glycosyl donor (20) by treatment with thiophenol and boron-trifluoride ethearate. A portion of 17 was converted to free trisaccharide GalNAcβ1-4(Fucα1-3)GlcNAc- Table III. β1-OMe 18 in three steps; removal of O-benzyl group by hydrogenolysis, and phthalamido removal followed by N-acetylation. The enzymatic synthesis of 18 has been reported (Bergwerff et al., 1993) .
followed by chloroacetylation and cleavage of the 4-methoxybenzylidene acetal with 70% aqueous acetic acid afforded compound 22 (unpublished observations) (Scheme II).
N-Iodosuccinimide-triflic acid glycosylation of compound (22) with glycosyl donor 20, followed by removal of the chloroacetyl groups in the β-galactopyranosyl residue afforded the partially-protected pentasaccharide intermediate (23) in 35% yield (based on 22). The 1 H NMR spectrum of 23 was in conformity with the overall structure expected.
Compound 23 is the key intermediate for obtaining the desired inhibitors 24 and 27. Thus, for the production of compound 24 the partially-protected 23 was subjected to complete removal of the blocking groups in three successive steps (see Materials and methods), whereas for obtaining the sialylated compound 27, the same intermediate 23 was allowed to react with known (Marra and Sinay, 1989) sialyl donor (25) to give, in 47% yield, the hexasaccharide derivative (26) (Scheme III). The α-configuration for the sialic acid residue was confirmed by the 1 H NMR of 26 which exhibited a double doublet at δ 2.67 (J = 4.6 Hz), attributable to H-3e of this residue. The conversion of 26 into the target compound (27) was performed in four successive steps: (1) lithium iodide-pyridine (Nicolaou et al., 1992) (methyl ester to free acid), (2) methanol-hydrazine hydrate (removal of the phthalimido group), (3) acetic anhydride-methanol-dichloromethane (N-acetylation), and (4) methanolic sodium methoxide (O-deacetylation). The 1 H and 13 C NMR spectra of 27 were in accord with the structure assigned.
A similar glycosylation of compound ) (28) with 20 gave, in 76% yield, the pentasaccharide derivative (29), the chloroacetyl group of which was removed to give, in 71% yield, intermediate (30) (Scheme IV).
For the production of the target compound (31), intermediate 30 was treated with five molar equivalents of sulfur trioxide-pyridine complex in N,N-dimethylformamide at 0_C (Scheme IV), followed by customary removal of the protecting groups. Column chromatographic purification on silica gel then furnished the desired compound 31 in 37% yield. The structure and purity of our synthetic compounds was established by TLC, NMR, and FAB mass spectroscopy. 
Inhibition studies
To ascertain the importance of GalNAc in the GalNAcLe x structure, we synthesized the two compounds shown in Table I , and compared their inhibitory properties against all three selectins. As shown in the table, the presence of a β-linked GalNAc residue at the 4 position of GlcNAc(Fucα1-3) was clearly superior to having the α2-3sialylated Gal residue (Neu5Ac2-3Gal) of SLe x , structure 1. These data confirm the previous report for E-selectin (Grinnell et al., 1994) , and extend them to show that GalNAcLe x is an even better inhibitor than SLe x of L-and P-selectin.
Based upon this finding and the rationale discussed in the introduction, we felt that Neu5Acα2-3Galβ1-3GalNAc sequence in Core 2 structure ligands could combine with GalNAcLe x to obtain even better binding to L-and P-selectin. We have therefore synthesized an oligosaccharide containing both of these sequences. The results of inhibition studies shown in Table  II support the value of this approach. It can be seen that putting the GalNAc-Le x into a Core 2 branched structure made no difference when compared to GalNAc-Le x . However, adding a sialic acid residue to the Galβ1-3GalNAc sequence of this structure potentiated the inhibitory properties to the point where it is ∼6-fold better as an inhibitor of L-and P-selectin. The improvement in binding to E-selectin was not as great. Interestingly, a sulfate ester at the 3-position of Galβ1-3GalNAc could not substitute for the sialic acid residue. These data suggest that L-and P-selectin are recognizing a specific clustered motif involving components of both branches of the Core 2 structure.
Our interest in the synthesis of branched ligands containing Neu5Acα2-Galβ1-3GalNAcα-arm has been also due to the following findings. We recently identified a 3-O-sulfotransferase from ovarian, breast, and other tissues capable of incorporating sulfate esters at C-3 of Gal in the Galβ1-3GalNAc sequence (Kuhns et al., 1995; Chandrasekaran et al., 1996 . Recently, reports of a native oligosaccharide carrying SE-3Galβ1-3Gal-NAc have appeared (Chance and Mawhinney, 1996; Florea et al., 1997) . We synthesized a branched derivative Core 2 structure 8, containing a 3-O-sulfate ester group instead of sialic acid moiety and found it to be inhibitory for L-and P-selectin (Koenig et al., 1997) . This encouraged us to synthesize 34 having the Neu5Acα2-3Galβ1-3GalNAc sequence.
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We also synthesized structure 9 wherein the sulfate ester is located at C-6 of Gal in the Galβ1-3GalNAc moiety
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In Table III , we have given the inhibition data for compounds 8, 32-34 and sialyl Lewis x . The carbohydrate sequence represented by structure 32 has been reported to be part of respiratory mucin (Lo-Guidice et al., 1994) .
Compound 32 was found to behave similar to sialyl Lewis x . Compound 33 was 2-fold better than sialyl Lewis x against E-selectin and slightly better against P-selectin. Comparative inhibition data of 8, 32, and 33 suggest that in core 2 structures, sialyl Lewis x arm is a preferred site for interacting with E-selectin. However, we have observed an interesting phenomena for L-and P-selectin ligands containing sulfate at the C-3 position of galactose on one arm and sialic acid at C-3 of galactose in the other arm of Core 2 structure. When sulfate is present at C-3 of Gal in Galβ1-3GalNAc the presence of sialic acid at C-3 of Gal in the Le x moiety further linked to C-6 of GalNAc (as in compound 33) has a negative impact toward binding, as our previous studies showed that Galβ1-4(Fucα1-3)GlcNAc-β1-6(SE-3Galβ1-3)GalNAcα1-OMe 8 is a 2-fold better ligand than sialyl Lewis x for L-and P-selectin (Koenig et al., 1997) . It is also surprising that when sialic acid is linked to C-3 of Gal in Galβ1-3GalNAc, the presence of a 3-O-sulfo Le x moiety on C-6 of GalNAc (as in compound 32) also has a negative impact. Our compound Galβ1-4(Fucα1-3)GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα1-OBn 34 (R.K.Jain and K.L.Matta, unpublished observations) is almost 3-fold better than sialyl Lewis x for L-selectin. It is apparent that in an approach for the construction of a library of analogs of the Galβ1-4(Fucα1-3)GlcNAc-β1-6(Galβ1-3)GalNAcα1-sequence if sialic acid (or replacement of sialic acid by a carboxy alkyl group) (Allanson, 1993 ) is kept at the C-3 position of galactose in one arm it will be advisable to introduce sulfate at a position other than C-3 of galactose in the other arm. Thus, it is not surprising to see a sulfate ester group located on C-6 of galactose or GlcNAc, as shown in 5 and 6 which represent portions of GlyCAM-1. Once again, our recent inhibition studies of these selectins with branched Core 2 structures warrant mention here. Interestingly, our synthetic compound 9 having SE-6Galβ1-3GalNAc is found to be a ligand for both L and P selectin. It is striking that 6′-sulfo Le x or 6-sulfo Le x type structures without a sialic acid moiety do not act as inhibitors of selectin, whereas the presence of a 6-O-sulfo group on the galactose moiety of Galβ1-3GalNAc showed inhibitory Downloaded from https://academic.oup.com/glycob/article-abstract/8/7/707/707504 by guest on 28 December 2018 effects. It should be noted that the SE-6Galβ1-3GalNAc sequence has been reported to be a part of various O-linked mucin glycoproteins (Chance et al., 1996) . Also, the Neu5Acα2-3(SE-6Gal)β1-3GalNAc sequence has been suggested to comprise a part of O-linked glycoprotein (Mawhinney et al., 1992) . Thus, it is quite possible that earlier mentioned naturally occurring selectin ligands such as CD34 or other unidentified sialo mucin type ligands (Kraal and Mebius, 1997) may contain 6′-sulfo Gal in the Galβ1-3GalNAc chain contained in a core 2 structure in the form of SE-6Galβ1-3GalNAc or SE-6(Neu5Acα2-3)Galβ1-3GalNAcα sequences. In fact, the present studies demonstrating the ability of Neu5Acα2-3Galβ1-3GalNAc to bind to selectins, combined with our previous finding of inhibitory impact of SE-6Galβ1-3GalNAc, enhances our interest in the preparation of branched core 2 structure with SE-6(Neu5Acα2-3)Galβ1-3GalNAc having sialyl Le x or Le x moiety O-linked at C-6 position of GalNAc.
It is not clear at this time why an oligosaccharide containing GalNAcβ1-4(Fucα1-3)GlcNAcβ1-OMe sequence, which lacks a negative charge, appears to be a better ligand for E-selectin. However, Grinnell et al. (1994) reported SLe x and GalNAc-β1-4(Fucα1-3)GlcNAc appear to be structurally similar through modeling studies. We became interested in the synthesis of oligosaccharides containing GalNAcβ1-4(Fucα1-3)GlcNAc determinant partly because GalNAc as a starting material is cheaper than sialic acid. Moreover, the chemical synthesis of an oligosaccharide containing the GalNAcβ1-4(Fucα1-3)GlcNAc determinant is not as time consuming as an oligosaccharide with sialyl Lewis x moiety. GalNAcβ1-4(Fucα1-3)GlcNAcβ-sequence has been found to be a part of various glycoproteins, especially N-linked glycoproteins (Dell et al., 1995; Manzella et al., 1996) . The disaccharide GalNAcβ1-4GlcNAcβ-is part of certain O-linked glycoproteins (Hirano et al., 1993) , some containing fucose (Siciliano, 1994) . The sequence GalNAc-β1-4(Fucα1-3)GlcNAc has been reported to be a part of oligosaccharides isolated from sea squirt H antigen, an O-linked glycoprotein (Ohata et al., 1991) . The sequence shown in structure 24 has been reported recently (Strecker et al., 1994) .
Thus, our present studies provide a new avenue toward the synthesis of GalNAc-Le x containing branched ligands for the inhibition of L-and P-selectin that is considerably better than SLe x . Furthermore, we have clearly demonstrated that the Neu5Acα2-3Galβ1-3GalNAc sequence of the core 2 structure contributes to the binding of L-and P-selectin.
Materials and methods

Materials
Sources of several chemicals used are indicated below. Most of the other materials used were obtained from the Sigma Chemical Co. The following materials were obtained from the sources indicated All other chemicals were of reagent grade or better, from commercial sources. The recombinant L-selectin Ig-fusion chimeric protein was prepared as described (Norgard et al., 1993) , and the E-and P-selectin Ig-fusion chimeric constructs were produced using the pcDM8 vectors .
ELISA inhibition assays
ELISA inhibition assays were done as previously reported (Koenig et al., 1997) . Sterile polystyrene 96 well ELISA plates (no. 25801, Corning) were coated with 200 ng of polyacrylamideSLe x (no. 18205PA, Syntesome) by overnight incubation at 4_C in 100 µl of 50 mM sodium carbonate/bicarbonate buffer, pH 9.5. Plates were then blocked with 200 µl per well of assay buffer: 20 mM Hepes (no. 16926, U.S. Biochemical), 125 mM NaCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 1% protease-free BSA (no. 82-045-1, Pentex, Miles, Inc.), pH 7.45 (osmolality 290 milliosmoles, determined with a Vapor Pressure Osmometer, model 5500XR, Wescor, Inc.) for a minimum of 2 h at 4_C. During the blocking step, the selectin chimeras were separately preincubated at 4_C with a secondary antibody, peroxidase-conjugated goat anti-human IgG (No. 109-035-098, Jackson Immunoresearch Laboratories, Inc.) in assay buffer for ∼1 h. Final selectin-Rg concentration was 20 nM, and the optimal secondary antibody dilution was determined to be 1:1000 for the particular serum used. Potential inhibitors were serially diluted in assay buffer, at 2× the final required concentration. The selectin-Rg/secondary antibody stock was aliquoted into tubes containing an equivalent volume of inhibitor solution; buffer alone for the positive control, or buffer with 10 mM Na 2 EDTA, pH 7.5, for the negative control (giving a final concentration of 5 mM EDTA). These tubes were preincubated at 4_C for 30 min, and then added to ELISA plates, in duplicates, at final well volume of 100 µl. After 4 h of plate incubation at 4_C, plates were washed three times with 200 µl per well of assay buffer at 4_C, followed by development with 150 µl per well of OPD solution at room temperature: 0.002 mg o-phenylenediamine dihydrochloride (OPD)/ml in 50 mM sodium citrate, 50 mM disodium phosphate buffer, pH 5.2 containing 1 µl/ml 30% H 2 O 2 . Using a timer, each well was sequentially quenched with 40 µl of 4 M H 2 SO 4 after a fixed time of peroxidase reaction. Softmax software and a microplate reader (Molecular Devices, Inc.) determined and recorded absorbance at 492 nM. Prior to curve fitting, the data was changed into percentages for comparative purposes, using the formula: ([average of duplicates) -(negative control)]/[(positive control) -(negative control)] × 100) again with the Softmax software.
General methods
Optical rotations were measured at ∼25_C with a Perkin-Elmer 241 Polarimeter. Thin layer chromatography (TLC) was conducted on glass plates precoated with 0.25 mm layers of silica gel 60F-254 (Analtech GHLF uniplates). The compounds were located by exposure UV light or by spraying with 5% H 2 SO 4 in ethanol and charring, or by both techniques. The silica gel used for column chromatography was Baker Analyzed (60-200 mesh). NMR spectra were recorded at ∼25_C, 1 H-spectra with a Varian EM-390 at 90 MHz and with a Bruker AM-400 at 400 MHz, and the 13 C-spectra with a Bruker AM-400 at 100.6 MHz. All chemical shifts are referenced to tetramethylsilane. Solutions in organic solvents were generally dried with anhydrous sodium sulfate. Dichloromethane, N,N-dimethylformamide, 1,2-dichloroethane, benzene, and 2,2-dimethoxypropane were kept dried over 4 Å molecular sieves. Elemental analyses were performed by Robertson Laboratory, Madison, New Jersey, USA.
General procedure for glycosidation
Using 1-thiophenyl glycoside as glycosyl donor, a solution of the acceptors (1.0-1.2 mmol) and donor (1.0-1.5 mmol) and N-iodosuccinimide (2.5-3.0 mmol) in dichloromethane (20 ml, for preparation of compound 14, 23, and 29) or 1:1 dichloromethane-ether (30 ml, for compound 17), propionitrile (15 ml, for compound 26) was stirred for 0.5 h with 4 Å molecular sieves (2 g) under an argon atmosphere at 0_C (compound 14), or -40_C (compound 26) or -65_C (compound 23 and 29) . Then a dilute solution of trifluoromethanesulfonic acid (triflic acid, 0.2 ml in 10 ml dichloromethane or propionitrile) was added dropwise. Stirring was continued at the same temperature for an additional hour, and the acid was neutralized with aqueous sodium bicarbonate solution. The mixture was filtered (Celite bed), and the solids thoroughly washed with water, saturated sodium bicarbonate solution, 10% sodium thiosulfate solution, dried and concentrated under diminished pressure.
Phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-α/β-Dgalactopyranoside (11)
To a stirred solution of 10 (6.4 g, 13.4 mmol) in dichloromethane (70 ml) was added thiophenol (4.0 ml, 36.4 mmol) and BF 3 ethereate (4.0 ml, 28.4 mmol). Stirring was continued for 4 h at room temperature. The reaction mixture was then washed with aqueous sodium bicarbonate solution, water, dried, and concentrated. The residue was purified on a column of silica gel with a solvent gradient consisting of hexane-ethyl acetate 3:2 → 1:1 (v/v) to afford 11 (6.1 g, 84%); 
Methyl 6-O-acetyl-3-O-benzyl-2-deoxy-2-phthalimido-β-Dglucopyranoside (13)
To a cold (-30_C), stirred solution of methyl 3-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 12 (4.8 g, 11.6 mmol) in pyridine (50 ml) was added, dropwise, a solution of acetyl chloride (0.97 ml, 12.4 mmol) in pyridine-dichloromethane (1:2, 15 ml). Stirring was continued for 2 h at the same temperature, and then the mixture was kept overnight at 5-6_C. It was then cooled to O_C and methanol (5 ml) was added to decompose excess reagent. The solvents were removed under diminished pressure and the residue dissolved in dichloromethane. The organic layer was successively washed with 10% aqueous hydrochloric acid, water, saturated sodium bicarbonate solution, dried, and concentrated. The crude product was purified on a column of silica gel with a solvent gradient consisting of 40-50% ethyl acetate in hexane to give 13 (4. 
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-galactopyranosyl)-(1→4)-6-O-acetyl-3-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (14)
Glycosidation of 13 (4.0 g, 8.6 mmol) with 11 (6.0 g, 11.1 mmol) followed by silica gel column chromatography (solvent gradient consisting of hexane-ethyl acetate 3:2 → 1:1) afforded 14 (6.1 g, 52%); , 60.54; H, 5.08; N, 3.21. Found: C, 60.35; H, 5.11; N, 3.16 .
Methyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-galactopyranosyl)-(1→4)-6-O-acetyl-2-deoxy-2-phthalimido-β-Dglucopyranoside (15)
A mixture of compound 14 (1.0 g) and 10% Pd-C (1.0 g) in glacial acetic acid (20 ml) was shaken at ∼345 kPa. The suspension was then filtered (Celite bed), the solids were thoroughly washed with glacial acetic acid, and the combined filtrate and washings were concentrated under reduced pressure. The crude product was applied to a column of silica gel and eluted with hexane-ethyl acetate 2:3 → 1:4 (v/v). 
Methyl O-(2,3,4-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-galactopyranosyl)-(1→4)-O-[2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-(1→3)-O]-6-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (17)
Glycosidation of 17 (3.9 g, 5.0 mmol) with 16 (10.8 g, 20.0 mmol) in dichloromethane-ether (1:1, 100 ml) and purification of the crude product mixture by silica gel column chromatography 
Methyl O-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-(1→4)-O-[α-L-fucopyranosyl)-(1→3)-O]-2-acetamido-2-deoxy-β-D-glucopyranoside (18)
A mixture of 17 (0.3 g) and 10% Pd-C (0.8 g) in glacial acetic acid (20 ml) was shaken under hydrogen at ∼345 kPa for 16 h at room temperature. After processing as described for the preparation of 16 (from 12) and followed by phthalamido removal with hydrazine hydrate-ethanol (1:4; v/v) at 100_C for 16 h and N-acetylation with methanol-triethylamine-acetic anhydride 
O-(3,4,6-Tri-O-acetyl-2-deoxy-2-phthalimido-β-D-galactopyranosyl)-(1→4)-O-[(2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1→3)-O]-1,6-di-O-acetyl-2-deoxy-2-phthalimido-D-glucopyranose (19)
A solution of compound 17 (6.0 g) in glacial acetic acid (60 ml) was treated with 10% Pd-C (4.0 g) and the mixture was shaken for 16 h at room temperature under hydrogen (∼345 kPa). The suspension was then filtered (Celite bed) and the solids were thoroughly washed with methanol. The filtrate and washings were combined and concentrated and the residue was directly utilized in the next step. A solution of this residue in acetic acid (80 ml) and acetic anhydride (96 ml) containing conc. H 2 SO 4 (8.4 ml) was stirred for 16 h at 5_C. The mixture was then diluted with dichloromethane (700 ml), and successively washed with water, saturated aqueous sodium bicarbonate solution, water, dried, evaporated to dryness, and redissolved in dichloromethane. 
Phenyl O-(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-galactopyranosyl)-(1→4)-O-[(2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1→3)-O]-6-O-acetyl-2-deoxy-2-phthalimido-1-thio-α/β-d-glucopyranoside (20)
To a stirred solution of 19 (2.0 6, 1.8 mmol) in dichloromethane (40 ml) was added thiophenol (2.0 ml, 18 mmol) and BF 3 -ethereate (0.8 ml, 5.6 mmol). Stirring was continued for 5 h at room temperature. The reaction mixture was washed with aqueous sodium bicarbonate solution, water, dried, and concentrated. The residue was purified on a column of silica gel with a solvent gradient consisting of hexane-ethyl acetate 1:1 → 1:4 to afford 20 4, 3, 
)-(1→3)-O]-)6-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→6)-O-[(6-O-trimethylacetyl-β-D-galactopyranosyl)-(1→3)-O]-2-acetamido-2-deoxy-α-D-galactopyranoside (23) and Methyl O-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-(1→4)-O-[(α-L-fucopyranosyl)-(1→3)-O]-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→6)-O-[(β-D-galactopyranosyl)-(1→3)-O]-2-acetamido-2-deoxy-α-D-galactopyranoside (24)
Glycosidation of 22 (0.9 g, 1.26 mmol) with 20 (1.0 g, 0.88 mmol) followed by processing in the usual manner gave a crude product mixture which was directly employed in the next step without further purification. A solution of the crude product in 1:1 ethanol-dichloromethane (30 ml) containing thiourea (2.8 g, 37.8 mmol) and lutidine (2.0 ml, 18.72 mmol) was stirred for 6 h at 80_C. The solvents were evaporated under reduced pressure and the residue redissolved in dichloromethane. The organic layer was washed with water, dried, and concentrated under diminished pressure. The residue was purified on a column of silica gel by elution with a solvent gradient consisting of 10-15% MeOH in dichloromethane to give 23 ( H, 6.77; N, 4.34. Found: C, 46.08; H, 6.63; N, 4, 3, -[methyl-(5-acetamido-4,7,8,9-tetra-O-a cetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonate-(2→3)-O-(6-O-trimethylacetyl-β-D-galactopyranosyl-(1→3)-O]-2-acetamido-2-deoxy-α-D-galactopyranoside (26) Compound 23 (0.2 g, 0.13 mmol) was treated with donor 25 (0.6 g, 1.1 mmol) in propionitrile (15 ml) at -65_C for 3 h. The reaction mixture was then processed as described above, and the crude product subjected to column chromatography on silica gel with 10% MeOH in dichloromethane as the eluent to give 26 (0. 
Methyl O-(2-acetamido-2-deoxy-β-D-galactopyranosyl-(1→4)-O-[α-L-fucopyranosyl)-(1→3)-O]-(2-acetamido-2-deoxy-β-Dglucopyranosyl)-(1→6)-O-[(5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→3)-O-(β-Dgalactopyranosyl)-(1→3)-O]-2-acetamido-2-deoxy-α-D-galactopyranoside (27)
A solution of 26 (0.1 g, 0.05 mmol) and lithium iodide (0.3 g, 2.2 mmol) in pyridine (10 ml) was stirred for 6 h at ∼120_C. The solvent was then removed under diminished pressure and the residue was passed through a small column of silica gel by elution with 20-30% methanol in dichloromethane to give the protected free acid derivative. This compound was taken in methanol-hydrazine hydrate (4:1, 20 ml) and heated at ∼80_C for 16 h. After evaporation to dryness, the residue was redissolved in methanoldichloromethane (1:1, 20 ml) and treated with acetic anhydride (6 ml) for 1 h at 0_C. The mixture was then evaporated to dryness and the residue so obtained was deacetylated by stirring in methanolic sodium methoxide (0.05 N; 20 ml) for 2 days at room temperature. The crude product was purified by column chromatography on silica gel by using chloroform/methanol/water , 45.46; H, 6.60; N, 4.42. Found: C, 45.37; H, 6.62; N, 4, 
Compound 28 (0.92 g, 1.5 mmol) was treated with 20 (1.5 g, 1.3 mmol) as described in the general glycosidation methods. After the customary processing, the crude product was purified by silica gel column chromatography with a solvent gradient consisting of 20-25% acetone in dichloromethane to give 29 (1.0 g, 74%); Anal Calc. for C 71 H 84 N 3 O 38 Cl: C, 52.55; H, 5.22; N, 2.59. Found: C, 52.31; H, 5.16; N, 4, 3, 
)-(1→3)-O]-(6-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→6)-O-[(2,4,6-tri-O-acetyl-β-D-galactopyrano syl)-(1→3)-O]-2-acetamido-2-deoxy-α-D-galactopyranoside (30)
Compound 29 (0.96 g, 0.58 mmol) was de-O-chloroacetylated in a manner analogous to that described for the preparation of 14. After customary processing, silica gel column chromatographic purification (5-10% MeOH in dichloromethane), gave 30 ( 
Methyl O-(2-acetamido-2-deoxy-β-D-galactopyranosyl-(1→4)-O-[α-L-fucopyranosyl-(1→3)-O]-(2-acetamido-2-deoxy-β-Dglucopyranosyl)-(1→6)-O-[(3-O-sulfo-β-D-galactopyranosyl sodium salt)-(1→3)-O]-2-acetamido-2-deoxy-α-D-galactopyranoside (31)
Compound 30 (0.45 g, 0.29 mmol) in N,N-dimethylformamide (20 ml) was treated with sulfur trioxide-pyridine complex (0.25 g, 1.6 mmol) at 0_C for 5 h. Excess reagent was destroyed by the addition of methanol (∼5 ml), followed by pyridine (∼5 ml). The mixture was then concentrated under diminished pressure and the residue was passed through a small column of silica gel by using 15-20% methanol in dichloromethane as the eluent. The fractions corresponding to product were pooled and concentrated and the residue taken in methanol-hydrazine hydrate (4:1, 50 ml) and heated at ∼90_C for 5 h. The mixture was then concentrated and the crude product mixture was taken in methanol-triethylamine (2:1, 24 ml), cooled (0_C) and treated with acetic anhydride (5 ml). It was allowed to gradually attain room temperature and kept for an additional 1 h at same temperature. The mixture was concentrated, and the residue applied to a column of silica gel and eluted with chloroform/methanol/water 13:6:1 and 4:5:1 (v/v/v). Fractions corresponding to product were pooled and concentrated and the residue redissolved in water and passed through a small column of Amberlite IR-120 (Na + ) cation exchange resin. Lyophilization of the eluate then furnished 31 (0.11 g, 37%), Anal Calc. for C 37 H 62 N 3 O 28 .SNa. 2 H 2 O: C, 40.84; H, 6.11; N, 3.86. Found: C, 40.73; H, 6.15; N, 3.73. 
